a.sorensen

TL2 Moderator · Plovdiv

Contributes reviews on supplier material. Based in Plovdiv.

Joined 28 September 2024 · last posted 1d

74Posts here

0Topics

0Solutions

662Likes received

718Likes given

18Badges

175Days visited

3kPosts read

Recent activity

Full stream

Coming back to: Why I now write the concentration on the vial in marker Replied, post #13 · Practice › Reconstitution · 27 Jul 2026 · 2 likes post #12 answers the question as asked. The question underneath it is different. Foaming during reconstitution: bubbles in the solution are usually just air…
Immortal time bias in a claims-database study — one year on Replied, post #43 · Evidence › Study critique · 25 Jul 2026 · 8 likes For anyone arriving from a search: the marked solution above is the direct answer, and the replies underneath it add the caveats that make it safe to use.
Why retatrutide discussion here is more cautious than elsewhere — one year on Replied, post #89 · Compounds › Retatrutide · 24 Jul 2026 · 24 likes Mass and identity: a report on retatrutide should state the mass detected by LC-MS, not assume a theoretical mass. The theoretical mass is not published in…
[2026 update] Travelling with an injectable: documentation and practicalities Replied, post #99 · Access › International · 22 Jul 2026 · 0 likes Licensed prescribing: where a compound is approved, prescribing is restricted to licensed prescribers. Where it is not approved, the legality of possession and use is…
Documenting a supplier's response to a discrepancy Replied, post #42 · Sourcing › Vendor reports · 19 Jul 2026 · 6 likes Coming back to post #40, because the follow-up matters more than the original answer. Having read the exchange above, I think I was wrong earlier in this topic and I…
Revisiting: Journal club: SURMOUNT-OSA and a hard endpoint in a soft field Replied, post #116 · Evidence › Journal club · 18 Jul 2026 · 17 likes PIONEER 6 (N Engl J Med 2019): Cardiovascular safety trial for oral semaglutide, not efficacy. Non-inferiority for safety was met. The trial was not designed to…
What a certificate commits its issuer to Replied, post #40 · Analytics › COA interpretation · 16 Jul 2026 · 0 likes Worth separating two things that post #36 runs together. Counter-ion form is crucial: peptides are isolated as salts, most often trifluoroacetate from reversed-phase…
Osteoarthritis and mechanical versus metabolic improvement — one year on Replied, post #12 · Clinical › Comorbidities · 9 Jul 2026 · 15 likes Obstructive sleep apnoea: SURMOUNT-OSA used an objective endpoint, the apnoea-hypopnoea index. Reduction was substantial. Whether the benefit is weight loss or a direct…
Prior authorisation: what the criteria usually require — a second dataset Replied, post #10 · Access › Insurance & coverage · 8 Jul 2026 · 3 likes On post #6 — agreed on the reasoning, with one qualification. Tier placement and step therapy: some formularies place a medication on a higher tier or require you to…
Revisiting: Journal club: SURMOUNT-OSA and a hard endpoint in a soft field Replied, post #76 · Evidence › Journal club · 2 Jul 2026 · 0 likes SURMOUNT-1 (N Engl J Med 2022): Tirzepatide obesity trial. The largest mean weight reduction for a pharmacological intervention at publication. Read the categorical…
I joined for one answer and stayed for a year — what changed my mind Replied, post #44 · Start Here › Welcome · 26 Jun 2026 · 12 likes The moderation log is public. Every staff action is logged with the rule cited and the reasoning stated. If you get moderated, the explanation is there and it is worth…
Asking a follow-up: new topic or new reply? Replied, post #10 · Start Here › How to Ask · 14 Jun 2026 · 7 likes On post #6 — agreed on the reasoning, with one qualification. Questions you cannot explain: "I cannot say why I am asking this, but is this compound stable at room…